Trade Summary

4 days ago, Burrows Scott L, serving as Chief Financial Officer at Spyre Therapeutics, Inc. (SYRE), sold 7,500 shares at $71.06 per share, for a total transaction value of $532,936.98. Following this transaction, Burrows Scott L now holds 97,994 shares of SYRE.

This sale represents a 7.11% decrease in Burrows Scott L's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, June 1, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, June 4, 2026 (accepted Jun 3, 9:30 PM ET), 3 days after the trade was made.

Spyre Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.